Release Date: July 13, 2020
Expiration Date: July 13, 2021

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The approval of ruxolitinib established JAK inhibitor therapy as the standard of care for intermediate- and high-risk myelofibrosis (MF), and the recent approval of fedratinib further supports the important role of JAK inhibitors in this setting. There is an urgent need for novel targeted therapies and new approaches. This article summarizes some of the most compelling data from key clinical trials investigating novel treatment approaches for MF and concludes with strategies to improve physician-patient communication.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelofibrosis.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Assess recent data from clinical trials evaluating novel targeted therapies and new treatment approaches for myelofibrosis
• Discuss the gaps in physician-patient communication regarding myelofibrosis and its impact on treatment decisions

Agenda

Future Directions in Myelofibrosis Therapy: Emerging Novel Agents and New Treatment Strategies - Elizabeth Hexner, MD

Instructions for Participation and Credit

This activity is eligible for credit through July 13, 2021. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Elizabeth Hexner, MD
Associate Professor of Medicine
Hospital of the University of Pennsylvania
Medical Director
Center for Cellular Immunotherapies
Philadelphia, Pennsylvania

Dr. Elizabeth Hexner is an Associate Professor of Medicine at the Hospital of the University of Pennsylvania and Medical Director at the Center for Cellular Immunotherapies in Philadelphia, Pennsylvania. She also serves as the Associate Director of the NIH CTSA-funded Masters in Translational Research program, where she co-directs a graduate level course in cell and gene therapy. Dr. Hexner’s two major research interests in malignant hematology include cellular therapies/hematopoietic stem cell transplantation, and experimental therapeutics in myeloproliferative neoplasms (MPN).

Accreditation

CME CREDIT Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: MediCom Worldwide, Inc. designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for .25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-028-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Elizabeth Hexner has received honoraria related to formal advisory activities from the American Board of Internal Medicine (ABIM), Blueprint Medicines, the Data Safety Monitoring Board (DSMB), and the Hematology Exam Committee. She has received grant support related to research activities from Kartos Therapeutics, Inc., Novartis AG, and Samus Therapeutics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Incyte Corporation

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.